Shots:
- The company has introduced SC formulation of Tyenne, a biosimilar of Actemra, to treat chronic autoimmune diseases across the US. It is available in the form of prefilled syringe & an autoinjector
- The IV formulation of the biosimilar was introduced in Apr 2024 after the US FDA’s approval on Mar 05, 2024
- Tyenne, an IL-6 receptor antagonist, is intended for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis & systemic juvenile idiopathic arthritis
Ref: Fresenius Kabi | Image: Fresenius Kabi | Press Release
Related News:- Just-Evotec Biologics and Sandoz Expand their Collaboration for Biosimilar
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
